Literature DB >> 1993029

Falls in elderly patients with glaucoma.

R J Glynn1, J M Seddon, J H Krug, C R Sahagian, M E Chiavelli, E W Campion.   

Abstract

We analyzed the determinants of serious falls among 489 ambulatory elders aged 65 years and older who received a comprehensive examination at a glaucoma consultation service. For the previous year, at least one fall requiring medical attention or restricted activity was reported by 9.6% (95% confidence interval [CI], 7.0% to 12.2%) of participants. Using logistic regression to adjust for potential confounding variables, the greatest single risk factor for falls was the use of nonmiotic topical eye medications (odds ratio [OR], 5.4; 95% Cl, 1.8 to 16.4). Additional risk factors for falls were female sex (OR, 2.3; 95% Cl, 1.1 to 4.7) and use of cardiac medications (OR, 2.5; 95% Cl, 1.1 to 5.6). Three other characteristics were also associated with the risk of falls: use of miotic eye medications (OR, 3.2; 95% Cl, 1.0 to 10.1); visual field impairment of 40% or greater (OR, 3.0; 95% Cl, 0.94 to 9.8); and use of sedatives (OR, 2.4; 95% Cl, 0.89 to 6.7). These findings suggest that ocular and systemic medications are the major predictors of falls even in this elderly population seeking ophthalmologic care for glaucoma. Medications appear to pose a greater risk for falls than even major visual impairment.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1993029     DOI: 10.1001/archopht.1991.01080020051041

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  21 in total

Review 1.  Medical treatment of glaucoma--a reappraisal of the risks.

Authors:  P Diggory; W Franks
Journal:  Br J Ophthalmol       Date:  1996-01       Impact factor: 4.638

2.  Effects of glaucoma medications on the cardiorespiratory and intraocular pressure status of newly diagnosed glaucoma patients.

Authors:  A Waldock; J Snape; C M Graham
Journal:  Br J Ophthalmol       Date:  2000-07       Impact factor: 4.638

3.  Delaying treatment of ocular hypertension: the ocular hypertension treatment study.

Authors:  Michael A Kass; Mae O Gordon; Feng Gao; Dale K Heuer; Eve J Higginbotham; Chris A Johnson; John K Keltner; J Philip Miller; Richard K Parrish; M Roy Wilson
Journal:  Arch Ophthalmol       Date:  2010-03

4.  Evaluation of Postural Control in Patients with Glaucoma Using a Virtual Reality Environment.

Authors:  Alberto Diniz-Filho; Erwin R Boer; Carolina P B Gracitelli; Ricardo Y Abe; Nienke van Driel; Zhiyong Yang; Felipe A Medeiros
Journal:  Ophthalmology       Date:  2015-04-16       Impact factor: 12.079

Review 5.  Beta blockers and the elderly with glaucoma: are we adding insult to injury?

Authors:  E O'Donoghue
Journal:  Br J Ophthalmol       Date:  1995-09       Impact factor: 4.638

6.  Tutorial on Biostatistics: Linear Regression Analysis of Continuous Correlated Eye Data.

Authors:  Gui-Shuang Ying; Maureen G Maguire; Robert Glynn; Bernard Rosner
Journal:  Ophthalmic Epidemiol       Date:  2017-01-19       Impact factor: 1.648

Review 7.  Are we blind to injuries in the visually impaired? A review of the literature.

Authors:  R Legood; P Scuffham; C Cryer
Journal:  Inj Prev       Date:  2002-06       Impact factor: 2.399

8.  The relationship between visual function, duration and main causes of vision loss and falls in older people with low vision.

Authors:  Ecosse Lamoureux; Sandeep Gadgil; Konrad Pesudovs; Jill Keeffe; Eva Fenwick; Mohamed Dirani; Satu Salonen; Gwyn Rees
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-04       Impact factor: 3.117

9.  Sources of binocular suprathreshold visual field loss in a cohort of older women being followed for risk of falls (an American Ophthalmological Society thesis).

Authors:  Anne Louise Coleman
Journal:  Trans Am Ophthalmol Soc       Date:  2007

Review 10.  Falls in the community-dwelling older adult: a review for primary-care providers.

Authors:  Theresa A Soriano; Linda V DeCherrie; David C Thomas
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.